You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Virotherapy, Oncolytic

Showing 1 - 25 of 144
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Biliary Tract Cancer Trial (H101, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Advanced Biliary Tract Cancer
  • (no location specified)
Apr 11, 2023

Hepatocellular Carcinoma Trial (Oncorine, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Jan 30, 2023

Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma Trial in Duarte, Chicago (Neural stem cells loaded with an

Completed
Has Results
  • Glioma
  • +7 more
  • Neural stem cells loaded with an oncolytic adenovirus
  • Duarte, California
  • +1 more
Dec 28, 2022

Refractory Malignant Ascites Trial in Shanghai (H101, Tislelizumab)

Recruiting
  • Refractory Malignant Ascites
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 2, 2022

Pancreatic Ductal Adenocarcinoma Trial in Shanghai (H101, Tislelizumab, lenvatinib)

Recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 30, 2022

Lymphoproliferative Disorder, HHV-8, Malignancy Trial run by the National Cancer Institute (NCI) (Etoposide, Interferon-alpha,

Active, not recruiting
  • Lymphoproliferative Disorder
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022

Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma, Recurrent Anaplastic Oligodendroglioma Trial in Duarte

Withdrawn
  • Recurrent Anaplastic Astrocytoma
  • +7 more
  • Neural Stem Cells-expressing CRAd-S-pk7
  • Resection
  • (no location specified)
Nov 22, 2022

Uterine Cervical Tumors, Oncolytic Virotherapy, Camrelizumab Trial in China (Recombinant human adenovirus type 5+Camrelizumab)

Not yet recruiting
  • Uterine Cervical Neoplasms
  • +2 more
  • Recombinant human adenovirus type 5＋Camrelizumab
  • Hangzhou, Zhejiang, China
  • +3 more
Feb 8, 2022

Head Neck Cancer, Melanoma, Breast Cancer Trial in Shanghai (Recombinant L-IFN adenovirus injection)

Recruiting
  • Head and Neck Cancer
  • +6 more
  • Recombinant L-IFN adenovirus injection
  • Shanghai, Shanghai, China
    Shanghai Fengxian District Central Hospital
Jan 16, 2022

Oncolytic Virotherapy Trial in St. Petersburg (Double Recombinant Vaccinia Virus VV-GMCSF-Lact)

Recruiting
  • Oncolytic Virotherapy
  • Double Recombinant Vaccinia Virus VV-GMCSF-Lact
  • St. Petersburg, Russian Federation
    N.N. Petrov National Medical Research Center of Oncology
May 11, 2022

Multiple Myeloma Trial in Little Rock (MV-NIS)

Completed
Has Results
  • Multiple Myeloma
  • Little Rock, Arkansas
    University of Arkansas for Medical Science
Sep 23, 2020

Recurrent Malignant Mesothelioma, Stage IA Malignant Mesothelioma, Stage IB Malignant Mesothelioma Trial in Rochester

Completed
  • Recurrent Malignant Mesothelioma
  • +5 more
  • oncolytic measles virus encoding thyroidal sodium iodide symporter
  • +3 more
  • Rochester, Minnesota
    Mayo Clinic
Jan 8, 2021

Malignant Tumor Trial in Chengdu (Oncolytic Virus SDJ001, Oncolytic Virus YD06-1)

Recruiting
  • Malignant Tumor
  • Oncolytic Virus SDJ001
  • Oncolytic Virus YD06-1
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Oct 6, 2023

Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer Trial in Newport Beach, Orlando (GL-ONC1 alone, or in

Completed
  • Ovarian Cancer
  • +2 more
  • GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab
  • Newport Beach, California
  • +1 more
Jan 3, 2023

Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial in Rochester, Helsinki (TILT-123, Pembrolizumab)

Recruiting
  • Platinum-refractory Ovarian Carcinoma
  • Platinum-resistant Ovarian Cancer
  • TILT-123
  • Pembrolizumab
  • Rochester, Minnesota
  • +1 more
Aug 12, 2022

Solid Tumor Trial in Helsinki (TILT-123)

Recruiting
  • Solid Tumor
  • TILT-123
  • Helsinki, Uusima, Finland
  • +1 more
Dec 17, 2021

Supratentorial Tumors, Malignant, Malignant Glioma, Glioblastoma Trial in Birmingham, Columbus (G207)

Active, not recruiting
  • Supratentorial Neoplasms, Malignant
  • +6 more
  • G207
  • Birmingham, Alabama
  • +1 more
Jun 1, 2022

Breast Tumors, Tumor Metastasis Trial in Boston, Canton (CodaLytic)

Not yet recruiting
  • Breast Neoplasms
  • Neoplasm Metastasis
  • CodaLytic
  • Boston, Massachusetts
  • +1 more
Oct 28, 2022

Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer Trial in Orlando, Albuquerque

Recruiting
  • Platinum-resistant Ovarian Cancer
  • +6 more
  • olvimulogene nanivacirepvec
  • +3 more
  • Orlando, Florida
    AdventHealth Cancer Institute
Sep 1, 2022

Urothelial Carcinoma Trial in Miami, New Orleans, Rochester (MV-NIS)

Recruiting
  • Urothelial Carcinoma
  • MV-NIS
  • Miami, Florida
  • +2 more
Jun 15, 2021

Tumors, High Grade Glioma, Glioblastoma Multiforme Trial in Birmingham (Biological G207)

Not yet recruiting
  • Neoplasms
  • +7 more
  • Biological G207
  • Birmingham, Alabama
    Children's of Alabama
Jun 1, 2022

Metastatic Tumor, Advanced Tumor Trial in France (Pexa-Vec, Ipilimumab)

Completed
  • Metastatic Tumor
  • Advanced Tumor
  • Bordeaux, France
  • +4 more
Jul 22, 2022

Lung Cancer Trial (TILT-123, Pembrolizumab)

Not yet recruiting
  • Lung Cancer
  • TILT-123
  • Pembrolizumab
  • (no location specified)
Nov 5, 2023

Metastatic NSCLC, Metastatic Triple-negative Breast Cancer Trial in Houston (biological, drug, radiation)

Active, not recruiting
Has Results
  • Metastatic Non-small Cell Lung Cancer
  • Metastatic Triple-negative Breast Cancer
  • ADV/HSV-tk
  • +3 more
  • Houston, Texas
    Houston Methodist Cancer Center
Dec 28, 2022

Advanced Solid Tumors Trial in Hangzhou, Shanghai (Recombinant human IL-21 oncolytic vaccinia virus injection)

Not yet recruiting
  • Advanced Solid Tumors
  • Recombinant human IL-21 oncolytic vaccinia virus injection
  • Hangzhou, Zhejiang, China
  • +1 more
Jun 21, 2023